Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.

by Jordi Remon, Aurelie Swalduz, David Planchard, Sandra Ortiz-Cuaran, Laura Mezquita, Ludovic Lacroix, Cecile Jovelet, Etienne Rouleau, Camille Leonce, Frank De Kievit, Clive Morris, Greg Jones, Kelly Mercier, Karen Howarth, Emma Green, Maurice Pérol, Pierre Saintigny, Benjamin Besse
Published 2020-01-01